Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627472 | 0.89 | PTPN1 (0.44) | ALDH1A1PTPN1CYP2C19NR1H4ABCB1 | |
| SCHEMBL4489232 | 0.81 | CHRM2 (0.46) | ABCB1 | |
| SCHEMBL3956579 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MCL1CYP2C19NR1H4LMNA | |
| SCHEMBL4479857 | 0.78 | BACE1 (0.41) | — | |
| SCHEMBL14859966 | 0.77 | NPC1 (0.67) | ALDH1A1PTPN1LMNA | |
| SCHEMBL14859957 | 0.77 | NPC1 (0.61) | ALDH1A1CYP2C19LMNAMAPT | |
| SCHEMBL17659009 | 0.76 | ALDH1A1 (0.47) | ALDH1A1PTPN1CYP2C19NR1H4LMNA | |
| SCHEMBL4083554 | 0.75 | LMNA (0.60) | ALDH1A1CYP2C19LMNA | |
| SCHEMBL9643788 | 0.75 | LMNA (0.60) | ALDH1A1CYP2C19LMNA | |
| SCHEMBL4472145 | 0.74 | MRGPRX4 (0.49) | ALDH1A1MCL1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20060148817-A1 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1572664-A1 | PYRAZOLE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056782-A1 | PYRAZOLE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148817-A1 | Pyrazole compounds | NRAS, HSP90AB1, HSP90AA1 | ALDH1A1 883/4885PTPN1 189/4885MCL1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.